Tag Archives: SLL

December, 2018

October, 2018

June, 2018

May, 2018

April, 2018

  • 9 April

    FDA Accepts NDA and Grants Priority Review to Verastem’s Duvelisib

    BOSTON–(BUSINESS WIRE)–Verastem, Inc. (NASDAQ:VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) for its lead product …

September, 2017

  • 6 September

    Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

    BOSTON–(BUSINESS WIRE)–Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta …

February, 2016

March, 2015